Pharmacogenetics of the 5-lipoxygenase pathway in asthma

Clinical and Experimental Allergy, Supplement

Volumn 28, Issue 5, 1998, Pages 164-170

  Silverman, E ^a   In, K H ^a   Yandava, C ^a   Drazen, J M ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 CYCLOPENTYL 2 [4 (2 QUINOLINYLMETHOXY)PHENYL]ACETIC ACID; 3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; CINALUKAST; GENLEUTON; LEUKOTRIENE; LEUKOTRIENE A4; LEUKOTRIENE B4; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE; MONTELUKAST; OXYGENASE; PRANLUKAST; SYNTHETASE; TRANSCRIPTION FACTOR SP1; UNCLASSIFIED DRUG; VERLUKAST; ZAFIRLUKAST; ZILEUTON;

ARACHIDONIC ACID METABOLISM; ASTHMA; CONFERENCE PAPER; DRUG MECHANISM; ENZYME MECHANISM; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PRIORITY JOURNAL; TRANSCRIPTION REGULATION; TRANSLATION REGULATION;

EID: 0031766873     PISSN: 09602178     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2222.1998.028s5164.x     Document Type: Conference Paper

References (35)

1. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science 1983; 220:568-75.
2. Stene DO, Murphy RC. Metabolism of leukotriene E4 in isolated rat hepatocytes. Identification of beta-oxidation products of sulfidopeptide leukotrienes. J Biol Chem 1988; 263:2773-8.
3. Dennis EA, Rhee SG, Billah MM, Hannun YA. Role of phospholipase in generating lipid second messengers in signal transduction. Faseb J 1991; 5:2068-77.
4. Peters-Golden M, McNish RW. Redistribution of 5-lipoxygenase and cytosolic phospholipase A2 to the nuclear fraction upon macrophage activation. Biochem Biophys Res Commun 1993; 196:147-53.
5. Hammarberg T, Zhang YY, Lind B, Radmark O, Samuelsson B. Mutations at the c-terminal isoleucine and other potential iron ligands of 5-lipoxygenase. Eur J Biochem 1995; 230:401-7.
6. Funk CD, Hoshiko S, Matsumoto T, Radmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene. Proc Natl Acad Sci USA 1989; 86:2587-91.
7. Rola-Pleszczynski M. LTB4 and PAF in the cytokine network. Adv Exp Med Biol 1991; 314:205-21.
8. Drazen JM. Inhalation challenge with sulfidopeptide leukotrienes in human subjects. Chest 1986; 89:414-9.
9. Holgate ST, Bradding P, Sampson AP. Leukotriene antagonists and synthesis inhibitors: new directions in asthma therapy. J Allergy Clin Immunol 1996; 98:1-13.
10. Drazen JM, Lewis RA, Wasserman SI, Orange RP, Austen KF. Differential effects of a partially purified preparation of slow-reacting substance of anaphylaxis on guinea pig tracheal spirals and parenchymal strips. J Clin Invest 1979; 63:1-5.
11. Dahlén S-E, Hedqvist P, Hammarstrom S, Samuelsson B. Leukotrienes are potent constrictors of human bronchi. Nature 1980; 288:484-6.
12. Weiss JW, Drazen JM, Coles N, McFadden ER Jr, Weller PF, Corey EJ et al. Bronchoconstrictor effects of leukotriene C in humans. Science 1982; 216:196-8.
13. Israel E, Dermarkarian R, Rosenberg M, Sperling R, Taylor G, Rubin P et al. The effects of a 5-lipoxygenase inhibitor on asthma induced by cold, dry air. N Engl J Med 1990; 323:1740-4.
14. Israel E, Rubin P, Kemp JP, Grossman J, Pierson WE, Siegel SC et al. The effect of inhibition of 5-lipoxygenase by zileuton in mild to moderate asthma. Ann Int Med 1993; 119:1059-66.
15. 4 receptor antagonist, in subjects with bronchial asthma. Am J Respir Crit Care Med 1994; 150:618-23.
16. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticosteroids. Thorax 1997; 52:45-8.
17. Bergstrom S. Prostaglandins: members of a hormonal system. These physiologically very potent compounds of ubiquitous occurrence are formed from essential fatty acids. Science 1967; 157:382-91.
18. Rosenthal MD, Rzigalinski BA, Blackmore PF, Franson RC. Cellular regulation of arachidonate mobilization and metabolism. Prostaglandins Leukot Essent Fatty Acids 1995; 52:93-8.
19. Petrich K, Ludwig P, Kuhn H, Schewe T. The suppression of 5-Iipoxygenation of arachidonic acid in human polymorphonuclear leucocytes by the 15-lipoxygenase product (15S)-hydroxy-(5Z,8Z,11Z,13E) -eicosatetraenoic acid: structure-activity relationship and mechanism of action. Biochem J 1996; 314:911-6.
20. Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF et al. Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis. Nature 1990; 343:282-4.
21. Lepley RA, Fitzpatrick FA. Inhibition of mitogen-activated protein kinase kinase blocks activation and redistribution of 5-lipoxygenase in HL-60 cells. Arch Biochem Biophys 1996; 331:141-4.
22. Lepley RA, Fitzpatrick FA. Irreversible inactivation of 5-lipoxygenase by leukotriene A4. Characterization of product inactivation with purified enzyme and intact leukocytes. J Biol Chem 1994; 269:2627-31.
23. Pouliot M, Mcdonald PP, Khamzina L, Borgeat P, McColl SR. Granulocyte-macrophage colony-stimulating factor enhances 5-lipoxygenase levels in human polymorphonuclear leukocytes. J Immunol 1994; 152:851-8.
24. Jakobsson PJ, Steinhilber D, Odlander B, Radmark O, CIaesson HE, Samuelsson B. On the expression and regulation of 5-lipoxygenase in human lymphocytes. Proc Natl Acad Sci USA 1992; 89:3521-5.
25. Steinhilber D, Hoshiko S, Grunewald J, Radmark O, Samuelsson B. Serum factors regulate 5-lipoxygenase activity in maturating HL60 cells. Biochim Biophys Acta 1993; 1178:1-8.
26. Stankova J, Rolapleszczynski M, Dubois CM. Granulocyte-macrophage colony-stimulating factor increases 5-lipoxygenase gene transcription and protein expression in human neutrophils. Blood 1995; 85:3719-26.
27. Ponton A, Thirion JP, Sirois P. Repression of the 5-lipoxygenase gene by c-myb overexpression in differentiated HL-60 cells. Prostaglandins 1997; 53:49-58.
28. Hoshiko S, Radmark O, Samuelsson B. Characterization of the human 5-lipoxygenase gene promoter. Proc Natl Acad Sci USA 1990; 87:9073-7:
29. Courey AJ, Tjian R. Mechanisms of transcriptional control as revealed by studies of human transcription factor Sp1. In: McKnight SL, Yamamoto KR. (eds) Transcriptional Regulation. Cold Spring Harbor, NY. Cold Spring Harbor Press 1992: 743-769.
30. Khachigian LM, Linder V, Williams AJ, Collins T. Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science 1996; 271:1427-31.
31. Silverman ES, Khachigian LM, Lindner V, Williams AJ, Collins T. Inducible PDGF α-chain transcription in smooth muscle cells is mediated by Egr-1 displacement of Sp1 and Sp3. Am J Physiol-Heart Circ Phy 1997; 42:H1415-H1426.
32. Kharbanda S, Nakamura T, Stone R, Hass R, Bernstein S, Datta R et al. Expression of the early growth response 1 and 2 zinc finger genes during induction of monocytic differentiation. J Clin Invest 1991; 88:571-7.
33. Khachigian LM, Williams AJ, Collins T. Interplay of Sp1 and Egr-1 in the proximal platelet-derived growth factor a-chain promoter in cultured vascular endothelial cells. J Biol Chem 1995; 270:27679-86.
34. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK et al. Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997; 99:1130-7.
35. O'Byrne PM, Israel E, Drazen JM. Antileukotrienes in the treatment of asthma. Ann Intern Med 1997; 127:472-80.